Fundamental Analysis of Royalty Pharma Plc - Growth / Value Index
RPRX - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.213
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 17.89 | 14.49 | -94.80 % | |
| Price to Book | 1.45 | 1.63 | 30.03 % | 1.65 |
| Price to Sales | 6.38 | 6.98 | 30.80 % | |
| Enterprise Value to EBITDA Multiple | 19.27 | 14.81 | -64.31 % |
RPRX - Profitability Highlights
Profitability Analysis
Piotroski F Score - Good Value of 7.0
Company Earning excess return
During the past twelve months, the company has given a strong Net Margin of 35.69%
All key Trailing Twelve Months Margin growing by 15 %
Good Return On Capital Employed of 13.43
Good Return on Equity of 11.49% is achieved by the company
Low Earning Yield of 5.43 %
EPS decline for last four quarters
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 11.49 | 17.39 | 3766.93 % | 0.0484 |
| Return On Asset | 4.84 | 6.93 | 2619.31 % | 0.0296 |
| Net Profit Margin | 35.69 | 48.20 | 2417.46 % | 0.841 |
| Operating Profit Margin | 41.97 | 63.37 | 361.72 % | -12.99 |
| EBITDA Margin | 41.63 | 63.37 | 239.16 % | -12.99 |
Highlights
| Market Cap | 12298.25 M |
| Enterprise Value | 17956.53 M |
| Price/Book TTM | 1.45 |
| Outstanding Share | 450980 K |
| Float/ Outstanding Share | 86.06% |
| Dividend Yield | 3.01 % |
Share Holding
Guru Numbers
| Price/Graham No | 1.14 |
| Peter Lynch Ratio | 102.02 |
| Piotroski F Score | 7.00 |
| Altman Z Score | 1.91 |
| Sloan Ratio | -0.116 |
| Peter Lynch Fair Value | 0 |
RPRX - Growth Highlights
Growth Analysis
YoY Net Margin Jump by 2417.46%
Annual sales of the company is increased for three years in a row
Tsr Growth Index - Very Poor Score of 17.66
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 2238.49 M | 5.24 % | 4.70 % |
| Gross Profit | 2238.49 M | 5.51 % | 4.70 % |
| EBITDA | 931947 K | 256.95 % | 112.03 % |
| Net Profit | 798857 K | 2549.50 % | 99.03 % |
| EPS | 1.52 | 1824.71 % | NA |
RPRX - Stability Highlights
Stability Analysis
Cash ratio of 3.07
Interest Coverage of 0
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.940 | 25.83 % | 0.622 |
| Cash Ratio | 3.07 | 106.39 % | |
| Quick Ratio | 0 | 0 % | 12.52 |
| Shareholders Equity | 39.84 | -29.68 % | |
| Debt to EBITDA | 4.11 | -75.85 % |
Historical Valuation Ratios of Royalty Pharma Plc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Royalty Pharma Plc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Royalty Pharma Plc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Royalty Pharma Plc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)